X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    Wall Street Cautiously Optimistic After Gene Therapy Deals

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

The European Commission Grants VAL001 Orphan Drug Designation for the Treatment of Diffuse Large B-cell Lymphoma

Yuvraj_pawp by Yuvraj_pawp
23rd November 2016
in Research & Development

Respiratorius AB (publ.) has received Orphan Drug Designation for its drug candidate VAL001 following a decision by the European Commission.

VAL001 will at product launch be included in the EU Community Register of Orphan Medicinal Products.VAL001 is a combination of a HDAC inhibitor (valproic acid) and a steroid (prednisone) and referred to as a pretreatment before chemotherapy (R-CHOP), for the treatment of diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, and the most common type of non-Hodgkin lymphoma, which constitute 30% of the patients diagnosed with this type of cancer. DLBCL annually affects about 60 000 people in the United States and Europe. The forecast for the 5-year survival with standard treatment is estimated at 60-70%.

A clinical phase I/IIa study of VAL001 is on-going, in which all included patients have been treated, at Skåne Oncology Clinic, SUS Lund/Malmö, Oncology Clinic at the University Hospital in Uppsala and at the Cancer Centre, University Hospital in Umeå. In the study, VAL001 is given as pretreatment prior to chemotherapy with the addition of rituximab (R-CHOP), in the treatment of DLBCL. Results of the interim analysis of the phase I/IIa study is showing that VAL001 combined with R-CHOP is significantly better than the reference group which consisted of a matched population of the Swedish lymphoma registry, which is only treated with R-CHOP, for both 1-year survival (95% significance) and 2-year survival (90% significance).

About Orphan Drug Designation

To obtain orphan drug designation in the EU, the new investigational drug product drug must be intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10 000 persons in the EU and for which no satisfactory treatments exist or, where they do exist, where the new medicine will be of great benefit to those suffering from this condition. It can also be granted if a new product is not expected to provide a sufficient return to justify the investment in the development of a new drug.

In short, by obtaining orphan drug designation Respiratorius will obtain market exclusivity for ten years in the EU, from the date of marketing approval. In addition, Respiratorius will receive free consultation and scientific advice on contact with the European Medicinal Agency, which among other things includes support for designing clinical trial protocols and reduced costs for regulatory applications for the commercialization.

For further information, please contact:

Johan Drott
President Respiratorius
+46 709-22 41 40
johan.drott@respiratorius.com

 

Christer Fåhraeus
Chairman Respiratorius
+46 705-60 90 00
christer.fahraeus@respiratorius.com

 

About Respiratorius AB
Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases like cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the company portfolio also holds a project for improved diagnosis of certain cardiovascular diseases.

Previous Post

WUXI BIOLOGICS and PRIMA sign MOU and Announce Strategic Development and Manufacturing Partnership

Next Post

Philips enhances neurological diagnosis with the launch of IntelliSpace Portal 9.0

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

Philips enhances neurological diagnosis with the launch of IntelliSpace Portal 9.0

Latest News

Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In